All In Biotech

Drug Trial Radar · NCT05546268

Study of Oral MRT-2359 in Selected Cancer Patients

A Phase 1/2 Study of Oral MRT-2359 in Patients With MYC-Driven and Other Selected Solid Tumors Including Lung Cancer and Diffuse B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

Oct 12, 2022

Primary completion

Dec 2026

Study completion Nov 2027

Sponsor

Lead sponsor
Monte Rosa Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Sep 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or amplification of L-MYC and N-MYC genes, hormone receptor positive (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer and prostate cancer.

Conditions

  • NSCLC
  • SCLC
  • High Grade Neuroendocrine Cancer
  • DLBCL
  • L-MYC and N-MYC Amplified Solid Tumors
  • NSCLC With High or Low L-MYC or N-MYC Expression
  • HR-positive, HER2-negative Breast Cancer
  • Prostate Cancer

Interventions

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359.

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359.

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359.

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359.

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359 in conjunction with intramuscular administration of fulvestrant.

  • Oral MRT-2359Drug

    Orally administered tablets of MRT-2359 in conjunction with orally administered enzalutamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2DTime frame: 28 days
  2. Phase 2 Evaluates preliminary anti-tumor activity of MRT-2359 by overall response rate (ORR) as determined by RECIST 1.1Time frame: 56 days (up to approximately 24 months from screening to end of study participation

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • University of California San Diego

    San Diego, California

  • Yale University

    New Haven, Connecticut

  • University of Kansas Cancer Center

    Lawrence, Kansas

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Cancer Institute

    Detroit, Michigan

  • South Texas Accelerated Research Therapeutics (START) Midwest

    Grand Rapids, Michigan

  • Washington University

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Columbia University Irving Medical Centre

    New York, New York

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

  • South Texas Accelerated Research Therapeutics (START) Mountain Region

    West Valley City, Utah

  • Virginia Cancer Specialists Research Institute

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.